Clinical trial registration: NCT07058012." Clinical IO biomarker Minimal residual disease Monotherapy P2 data Residual disease Colorectal Cancer Oncology Solid Tumor June 11, 2026 Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (clinicaltrials.gov) - P2 | N=70 | Suspended | Sponsor: Thomas Jefferson University | Recruiting Suspended Trial suspension Basal Cell Carcinoma Head and Neck Cancer Non-melanoma Skin Cancer Oncology June 17, 2026 A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Memorial Sloan Kettering Cancer Center New P1 trial Head and Neck Cancer Nasopharyngeal Carcinoma Oncology Solid Tumor July 22, 2025 TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (IASLC-WCLC 2025) - P2 | "Introduction : SPRINT (NCT03523702) was a multi-center Phase II trial where biomarker-selected (PD-L1 TPS 50%) locally advanced non-small cell lung cancer (LA-NSCLC) patients were treated with 3 cycles of induction therapy with the PD-1 inhibitor pembrolizumab followed by risk-adapted radiotherapy (RT), then consolidation pembrolizumab to complete a 1-year course while chemotherapy was omitted (PMID: 37988638)...Thus, we hypothesize that dual IO with the PD-1 inhibitor cemiplimab plus the LAG-3 inhibitor fianlimab administered before and after thoracic RT, as per the SPRINT approach, has valuable potential as a biomarker-driven treatment regimen for LA-NSCLC patients...Safety will be assessed via a safety-run in phase and extended adverse events collection
it means a pharmacy cannot legally prepare them for a patient, even with a prescription
It is important to remember that individual responses to medication can vary, and what works for one person may not work for another
Stevenson for assistance in performing the clinical studies
Injecting it in the abdomen for a lumbar disc herniation significantly reduces its concentration at the target tissue
Common Skin & Aging Concerns from GLP-1 Medications 1
